Author warns investors to sell Novo Nordisk (NVO), calling it a value trap due to weak obesity-market competitiveness, no R&D, and a multi-year turnaround.
NVO — AVOID The author argues NVO is struggling to compete in the obesity market, with core business missing earnings and oral Wegovy growth dependent on a $200 promotional price that will fade when the promotion ends. They claim NVO has no R&D, evidenced by losing the Metsera bid, and is overexposed to obesity drugs facing patent losses and Eli Lilly competition. The turnaround is years away, making it a value trap with opportunity cost, and the author notes a 5-13% constant-currency revenue decline expected for 2026.
Value trap. Not value investing.
This Reddit post, published February 04, 2026, features u/Impossible_Device240 discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Impossible_Device240 · Tickers: NVO